Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti–PD-L1 to eliminate melanoma in mice

cGAS is essential for the antitumor effect of immune checkpoint blockade

(2017) Hua Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy

(2017) Yohei Takeda et al.   Cell Reports

The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells

(2017) Xueheng Guo et al.   Frontiers in Immunology

Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells

(2017) Hiroaki Shime et al.   OncoImmunology

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling

(2015) Michael Tang et al.   Cell Reports

Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice

(2015) S. Ueha et al.   Cancer Immunology Research

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists

(2015) K. Cheng et al.   Science Advances

Molecular Mechanisms of TLR2-Mediated Antigen Cross-Presentation in Dendritic Cells

(2014) K.-Y. Shen et al.   JOURNAL OF IMMUNOLOGY

Toll-Like Receptor Signaling Pathways

(2014) Takumi Kawasaki et al.   Frontiers in Immunology

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

Key roles of adjuvants in modern vaccines

(2013) Steven G Reed et al.   NATURE MEDICINE

Toll-Like Receptor Signaling

(2013) K.-H. Lim et al.   Cold Spring Harbor Perspectives in Biology

TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy

(2012) Laurent Amiset et al.   OncoImmunology

TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function

(2011) M. H. Nyirenda et al.   JOURNAL OF IMMUNOLOGY

TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

(2011) Y. Zhang et al.   JOURNAL OF IMMUNOLOGY

TLR2-Dependent Induction of IL-10 and Foxp3+CD25+CD4+ Regulatory T Cells Prevents Effective Anti-Tumor Immunity Induced by Pam2 Lipopeptides In Vivo

(2011) Sayuri Yamazaki et al.   PLoS One

Vaccine Adjuvants: Putting Innate Immunity to Work

(2010) Robert L. Coffman et al.   IMMUNITY

Identification of Novel Synthetic Toll-like Receptor 2 Agonists by High Throughput Screening

(2010) Yue Guan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

TLRs and innate immunity

(2008) B. A. Beutler   BLOOD

Toll-like Receptors Activate Innate and Adaptive Immunity by using Dendritic Cell-Intrinsic and -Extrinsic Mechanisms

(2008) Baidong Hou et al.   IMMUNITY